Silver nanoparticles inhibit VEGF-and IL-1β-induced vascular permeability via Src dependent pathway in porcine retinal endothelial cells

Journal of Nanobiotechnology

Volumn 7, Issue , 2009, Pages 8-

  Sheikpranbabu, Sardarpasha ^a   Kalishwaralal, Kalimuthu ^a   Venkataraman, Deepak ^a   Eom, Soo H ^b   Park, Jongsun ^c   Gurunathan, Sangiliyandi ^a  

^a KALASALINGAM UNIVERSITY   (India)

^b Gwangju Institute of Science and Technology (GIST)   (South Korea)

^c Chungnam National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CONSTITUTIVELY ACTIVES; DIABETIC RETINOPATHY; DOMINANT NEGATIVE; ENDOTHELIAL PERMEABILITY; IN-VITRO; INTERLEUKIN-1; OCULAR DISEASE; OVER-EXPRESSION; PLASMID ENCODING; SIGNALING MECHANISMS; SIGNALLING PATHWAYS; SILVER NANOPARTICLES; SOLUTE FLUX; SRC-KINASE; THERAPEUTIC TARGETS; VASCULAR ENDOTHELIAL GROWTH FACTOR; VASCULAR PERMEABILITY;

BLOOD VESSEL PROSTHESES; CAPILLARITY; DEXTRAN; EYE PROTECTION; GLUCOSE; MONOLAYERS; NANOPARTICLES; OPHTHALMOLOGY; PHOSPHORYLATION; SELF ASSEMBLY; SILVER; SUGAR (SUCROSE);

ENDOTHELIAL CELLS;

INTERLEUKIN 1BETA; NANOPARTICLE; SILVER; STEROID RECEPTOR COACTIVATOR 1; VASCULOTROPIN;

ANIMAL CELL; ARTICLE; BIOSYNTHESIS; BLOOD VESSEL PERMEABILITY; CELL MEMBRANE PERMEABILITY; CELL VIABILITY; CHEMICAL ANALYSIS; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; ENDOTHELIUM CELL; GENE OVEREXPRESSION; NONHUMAN; PLASMID; PROTEIN PHOSPHORYLATION; RETINA BLOOD VESSEL; SIGNAL TRANSDUCTION;

SUS;

EID: 70749155157     PISSN: None     EISSN: 14773155     Source Type: Journal    
DOI: 10.1186/1477-3155-7-8     Document Type: Article

References (46)

1. Harhaj NS, Antonetti DA. Regulation of tight junctions and loss of barrier function in pathophysiology. Int J Biochem Cell Biol 2004, 36:1206-37. 15109567, 10.1016/j.biocel.2003.08.007.
2. Senger R, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983, 219:983-5. 6823562, 10.1126/science.6823562.
3. Dvorak HF, Detmar M, Claffey KP, Nagy JA, Vandewater L, Senger DR. Vascular permeability factor/vascular endothelial growth factor: an important mediator of angiogenesis in malignancy and inflammation. Int Arch Allergy Immunol 1995, 107:233-5. 7542074, 10.1159/000236988.
4. Caldwell RB, Bartoli M, Behzadian MA, El-Remessy AEB, Al-Shabrawey M, Platt DH, Caldwell RW. Vascular endothelial growth factor and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives. Diabetes Metab Res Rev 2003, 19:442-455. 14648803, 10.1002/dmrr.415.
5. Boyd SR, Zachary I, Chakravarthy U, Allen GJ, Wisdom GB, Cree IA, Martin JF, Hykin PG. Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion. Arch Ophthalmol 2002, 120:1644-1650.
6. Qaum T, Xu Q, Joussen AM, Clemens MW, Qin W, Miyamoto K, Hassessian H, Wiegand SJ, Rudge J, Yancopoulos GD, Adamis AP. VEGF-initiated blood-retinal barrier breakdown in early diabetes. Invest Ophthalmol Vis Sci 2001, 42:2408-2413.
7. Antonetti DA, Barber AJ, Khin S, Lieth E, Tarbell JM, Gardner TW. Vascular permeability in experimental diabetes is associated with reduced endothelial occludin content: vascular endothelial growth factor decreases occludin in retinal endothelial cells. Diabetes 1998, 47(12):1953-1959. 9836530, 10.2337/diabetes.47.12.1953.
8. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006, 355:1419-1431. 17021318, 10.1056/NEJMoa054481.
9. Quagliarello VJ, Wispelwey B, Long WJ, Scheld WM. Recombinant human interleukin-1 induces meningitis and blood-brain barrier injury in the rat: Characterization and comparison with tumor necrosis factor. J Clin Invest 1991, 87(4):1360-6. 2010549, 10.1172/JCI115140, 295174.
10. Bamforth SD, Lightman SL, Greenwood J. Interleukin-1β-induced disruption of the retinal vascular barrier of the central nervous system is mediated through leukocyte recruitment and histamine. American Journal of Pathology 1997, 150(1):329-340. 1858506, 9006348.
11. Portney NG, Ozkan M. Nano-oncology: drug delivery, imaging, and sensing. Anal Bioanal Chem 2006, 384:620-30. 16440195, 10.1007/s00216-005-0247-7.
12. Park GE, Webster TJ. A review of nanotechnology for the development of better orthopedic implants. J Biomed Nanotechnol 2005, 1:18-29.
13. Gojova A, Guo B, Kota RS, Rutledge JC, Kennedy IM, Barakat IB. Induction of inflammation in vascular endothelial cells by metal oxide nanoparticles: effect of particle composition. Environ Health Perspect 2007, 115:403-09. 1849911, 17431490.
14. Frampton MW, Stewart JC, Oberdörster G, Morrow PE, Chalupa D, Pietropaoli AP, Frasier LM, Speers DM, Cox C, Huang LS, Utell MJ. Inhalation of ultrafine particles alters blood leukocyte expression of adhesion molecules in humans. Environ Health 2006, 114:51-58.
15. Rücker R, Phipps RP, Schneider A, Frampton M, Cyrys J, Oberdörster G, Wichmann HE, Peters A. Ultrafine particles and platelet activation in patients with coronary heart disease-results from a prospective panel study. Part Fibre Toxicol 2007, 4:1. 10.1186/1743-8977-4-1, 17241467.
16. Boucher W, Stern JM, Kotsinyan V, Kempuraj D, Papaliodis D, Cohen MS, Theoharides TC. Intravesical nanocrystalline silver decreases experimental bladder inflammation. J Urol 2008, 179:1598-602. 18295255, 10.1016/j.juro.2007.11.037.
17. Bhol KC, Schechter PJ. Effects of nanocrystalline silver (NPI 32101) in a rat model of ulcerative colitis. Dig Dis Sci 2007, 52:2732-2742. 17436088, 10.1007/s10620-006-9738-4.
18. Mehta D, Malik AB. Signaling mechanisms regulating endothelial permeability. Physiol Rev 2006, 86(1):279-367. 16371600, 10.1152/physrev.00012.2005.
19. Davda J, Labhasetwar V. Characterization of nanoparticle uptake by endothelial cells. Int J Pharm 2002, 233(1-2):51-59. 11897410, 10.1016/S0378-5173(01)00923-1.
20. Martin SG, Murray JC. Gene-transfer systems for human endothelial cells. Adv Drug Deliv Rev 2000, 41:223-233. 10699317, 10.1016/S0169-409X(99)00068-X.
21. Parikh SA, Edelman ER. Endothelial cell delivery for cardiovascular therapy. Adv Drug Deliv Rev 2000, 42:139-161. 10942819, 10.1016/S0169-409X(00)00058-2.
22. Behzadian MA, Windsor LJ, Ghaly N, Liou G, Tsai NT, Caldwell RB. VEGF-induced paracellular permeability in cultured endothelial cells involves urokinase and its receptor. FASEB J 2003, 17(6):752-754.
23. Kalishwaralal K, Deepak V, Ramkumarpandian S, Nellaiah H, Sangiliyandi G. Extracellular biosynthesis of silver nanoparticles by culture supernatant of bacillus licheniformis. Materials Lett 2008, 62:4411-4413.
24. Kalimuthu K, Suresh Babu R, Venkataraman D, Bilal M, Gurunathan S. Biosynthesis of silver nanocrystals by bacillus licheniformis. Colloid Surf B: Bioint 2008, 65:150-53.
25. Gurunathan S, David D, Gerst JE. Dynamin and clathrin are required for the biogenesis of a distinct class of secretory vesicles in yeast. J EMBO 2002, 21:602-14.
26. Raposo G, Nijman HW, Stoorvogel W, Liejendekker R, Harding CV, Melief CJ, Geuze. B-lymphocytes secrete antigen-presenting vesicles. J Exp Med 1996, 183:1161-72. 8642258, 10.1084/jem.183.3.1161, 2192324.
27. Ristorcelli E, Beraud E, Verrando P, Villard C, Lafitte D, Sbarra V, Lombardo D, Verine A. Human tumor nanoparticles induce apoptosis of pancreatic cancer cells. J FASEB 2008, 22:3358-69.
28. Banumathi E, Haribalaganesh R, Sheik Pran Babu S, Sirish Kumar N, Sangiliyandi G. High-yielding enzymatic method for isolation and culture of microvascular endothelial cells from bovine retinal blood vessels. Microvasc Res 2009, 77:377-381. 19233216, 10.1016/j.mvr.2008.12.005.
29. Yang KJ, Shin S, Piao L, Shin E, Li Y, Park KA, Byun HS, Won M, Hong J, Kweon GR, Hur GM, Seok JH, Chun T, Brazil DP, Hemmings BA, Park J. Regulation of 3-phosphoinositide-dependent protein kinase-1 (PDK1) by Src involves tyrosine phosphorylation of PDK1 and Src homology 2 domain binding. J Biol Chem 2008, 283:1480-91. 18024423, 10.1074/jbc.M706361200.
30. Mukherjee P, Bhattacharya R, Wang P, Wang L, Basu S, Nagy JA, Atala A, Mukhopadhyay D, Soker S. Antiangiogenic properties of gold nanoparticles. Clin Cancer Res 2005, 11(9):3530-34. 15867256, 10.1158/1078-0432.CCR-04-2482.
31. Eliceiri BP, Paul R, Schwartzberg PL, Hood JD, Leng J, Cheresh DA. Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. Mol Cell 1999, 4(6):915-24. 10635317, 10.1016/S1097-2765(00)80221-X.
32. Kalishwaralal K, Banumathi E, Pandian SBRK, Deepak V, Muniyandi J, Eom SH, Sangiliyandi G. Silver nanoparticles inhibit VEGF induced cell proliferation and migration in bovine retinal endothelial cells. Colloid Surf B: Bioint 2009, 73(1):51-7.
33. Thurston G, Rudge JS, Ioffe E, Zhou H, Ross L, Croll SD, Glazer N, Holash J, M McDonald D, Yancopoulos GD. Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat Med 2000, 6:460-63. 10742156, 10.1038/74725.
34. Thurston G, Suri C, Smith K, McClain J, Sato TN, Yancopoulos GD, McDonald DM. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science 1999, 286:2511-4. 10617467, 10.1126/science.286.5449.2511.
35. Bouck N. PEDF: anti-angiogenic guardian of ocular function. Trends Mol Med 2002, 8:330-34. 12114112, 10.1016/S1471-4914(02)02362-6.
36. Dawson DW, Volpert OV, Gillis P, Crawford SE, Xu H, Benedict W, Bouck NP. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 1999, 285:245-48. 10398599, 10.1126/science.285.5425.245.
37. Stellmach V, Crawford SE, Zhou W, Bouck N. Prevention of ischemia-induced retinopathy by the natural ocular antiangiogenic agent pigment epithelium-derived factor. Proc Natl Acad Sci USA 2001, 98(5):2593-2597. 11226284, 10.1073/pnas.031252398, 30183.
38. Volpert OV, Zaichuk T, Zhou W, Reiher F, Ferguson TA, Stuart PM, Amin M, Bouck NP. Inducer-stimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium-derived factor. Nat Med 2002, 8(4):349-57. 11927940, 10.1038/nm0402-349.
39. Liu H, Ren JG, Cooper WL, Hawkins CE, Cowan MR, Tong PY. Identification of the antivasopermeability effect of pigment epithelium-derived factor and its active site. Proc Natl Acad Sci USA 2004, 101(17):6605-10. 15096582, 10.1073/pnas.0308342101, 404092.
40. Elechiguerra JL, Burt JL, Morones JR, Camacho-Bragado A, Gao X, Lara HH, Yacaman MJ. Interaction of silver nanoparticles with HIV-1. J nanobiotechnol 2005, 3:6.
41. Chithrani BD, Chan WCW. Elucidating the mechanism of cellular uptake and removal of protein-coated gold nanoparticles of different sizes and shapes. Nano Lett 2007, 7(6):1542-1550. 17465586, 10.1021/nl070363y.
42. Summy JM, Trevino JG, Lesslie DP, Baker CH, Shakespeare WC, Wang Y, Sundaramoorthi R, Metcalf CA, Keats JA, Sawyer TK, Gallick GE. AP2 a novel and highly potent Src family kinase inhibitor, reduces vascular endothelial growth factor and interleukin-8 expression in human solid tumor cell lines and abrogates downstream angiogenic processes. Mol Cancer Ther 3846, 4(12):1900-1911.
43. Erfurth US, Schrehard US, Cursiefen C, Michels S, Beckendorf A, Naumann GOH. Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 2003, 44:4473-4480. 14507895, 10.1167/iovs.02-1115.
44. Al-Ramadi BK, Welte T, Fernandez-Cabezudo MJ, Galadari S, Dittel B, Fu XY, Bothwell ALM. The Src-protein tyrosine kinase Lck is required for IL-1-mediated costimulatory signaling in Th2 cells. J Immunol 2001, 167(12):6827-33.
45. Weis S, Cui J, Barnes L, Cheresh D. Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis. J Cell Biol 2004, 167:223-9. 15504909, 10.1083/jcb.200408130, 2172541.
46. Criscuoli ML, Nguyen M, Eliceiri BP. Tumor metastasis but not tumor growth is dependent on Src-mediated vascular permeability. Blood 2005, 105:1508-14. 15486073, 10.1182/blood-2004-06-2246.